Hang Li,Leyuan Chen,Yiliang Li et al.
Hang Li et al.
Introduction: Cancer is currently one of the biggest killers threatening human health. More and more studies have confirmed that SUMO-specific protease 1 (SENP1) is over-expressed in various cancer tissues. Therefore, tar...
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present) [0.03%]
新型尿酸转运体1 (URAT1)抑制剂：近期专利文献综述（2020年至今）
Xiaoyu Shi,Tong Zhao,Edeildo Ferreira da Silva-Júnior et al.
Xiaoyu Shi et al.
Introduction: The urate transporter 1 (URAT1) is a membrane transporter located in the apical membrane of human renal proximal tubule epithelial cells, which mediates most of the reabsorption of urate. Hyperuricemia (HUA)...
Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022) [0.03%]
细胞周期检查点的抑制剂靶向Wee1激酶-专利回顾(2003-2022)
Jingxue Yan,Lili Zhuang,Yong Wang et al.
Jingxue Yan et al.
Introduction: DNA damage repair in most malignancies with mutation of p53 is more dependent on the G2/M checkpoint. Wee1 kinase is a key regulator of the G2/M checkpoint. If Wee1 is inhibited, it results in cells with unr...
An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022) [0.03%]
蛋白精氨酸N-甲基转移酶抑制剂的专利综述更新（2019-2022）
Jinyun Dong,Jilong Duan,Zi Hui et al.
Jinyun Dong et al.
Protein arginine methyltransferases (PRMTs), enzymes catalyzing the methylation of target proteins, play an essential role in maintaining functional homeostasis in normal physiology. Aberrant expressions and enhanced enzymatic activities of...
An updated patent review of IDO1 inhibitors for cancer (2018-2022) [0.03%]
癌症免疫治疗IDO1抑制剂专利综述（2018-2022）
Peng-Fei Wang,Li-Qiang Yang,Zhao-Hang Shi et al.
Peng-Fei Wang et al.
Introduction: Indoleamine 2,3-dioxygenase 1 (IDO1) is highly related to the immune evasion of a wide range of malignancies due to its role in the immune suppression caused by the depletion of tryptophan (Trp) and the accu...
Weiwei Han
Weiwei Han
Introduction: Drug patent linkage is an important mechanism for the early resolution of patent disputes in the pharmaceutical field. Since its establishment in China in mid-2021, the patent linkage system has drawn nation...
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021) [0.03%]
IL-17A/IL-17RA的小分子调节剂：专利回顾（2013-2021）
Bidong Zhang,Alexander Dömling
Bidong Zhang
Introduction: Interleukin-17A (IL-17A) is a well-established pro-inflammatory cytokine, which plays a pivotal role in immune and autoimmune diseases including psoriasis, asthma, psoriatic arthritis, and rheumatoid arthrit...
Recent advances in the development of STING inhibitors: an updated patent review [0.03%]
STING抑制剂开发的最新进展：最新的专利回顾
Ancheng Shen,Mingjie Chen,Qingxuan Chen et al.
Ancheng Shen et al.
Introduction: STING is at the center of the cGAS-STING signaling and acts as the hub of the innate immune system. Hyper-activation of STING has been observed in various severe autoimmune diseases, such as AGS, SLE, and ma...
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present) [0.03%]
2016年以来重排过程中转录的蛋白质（RET）激酶抑制剂专利综述更新
Baku Acharya,Brendan Frett
Baku Acharya
Introduction: Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase. Aberrations in RET signaling due to mutations, gene fusions, or overexpression can lead to carcinomas. Six inhibitors have be...
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001-2021) [0.03%]
二氢叶酸还原酶抑制剂的专利景观及临床研发阶段（2001-2021）
Kavita Bhagat,Nitish Kumar,Harmandeep Kaur Gulati et al.
Kavita Bhagat et al.
Introduction: Dihydrofolate reductase (DHFR) plays an important role in the biosynthesis of amino acid and folic acid. It participates by reducing dihydrofolate to tetrahydrofolate, in the presence of nicotinamide dinucle...